Johns Hopkins POC-IT: Point of Care Information Technology [Home]
HIV Guide
 Zambia HIV National Guidelines
 


Introduction  

HIV Counseling and Testing  

Sexually Transmitted Infections (STIs)  

General Principles of Antiretroviral Therapy for Chronic HIV Infection in Adults and Adolescents  

When to Start ARV Therapy for Chronic HIV Infection in Adults and Adolescents  

Initial Regimen for ARV Therapy  

Adherence  

Baseline evaluation and Monitoring  

Calculations: Ideal Body Weight, Body Mass Index and Creatinine Clearance  

ARV Therapy for Individuals with Tuberculosis Co-Infection  

Adverse Effects and Toxicity  

Immune Reconstitution Inflammatory Syndrome (IRIS)  

Changing or Stopping ART  

Treatment Failure  

Stopping ARV Therapy  

Post Exposure Prophylaxis  

Cotrimoxazole Prophylaxis  

WHO Staging in Adults and Adolescents  

Nutrition Care and Support  

Palliative Care in HIV and AIDS  

 Guide Editors
 Editor In Chief
    Joel E. Gallant, MD, MPH

Pharmacology Editor
    Paul Pham, PharmD, BCPS

Zambia Guideline Team
   Peter Mwaba MMed PhD FRCP
   Alywn Mwinga MMed
   Isaac Zulu MMed MPH
   Velepie Mtonga MMed
   Albert Mwango MBChB
   Jabbin Mulwanda MMed FCS
 

 

 

Diagnosis>Complications of Therapy>
HIV Guide Home PageEmail this module to a friend

Diabetes Mellitus and Insulin Resistance

Todd T. Brown, M.D. and Joseph Cofrancesco, Jr., M.D., M.P.H.
08-17-2009

Zambia Specific Information

  • Diabetes incidence/prevalence in Zambian HIV+ pts likely to increase over time as pts live longer with ART.
  • Review diet of diabetics carefully in Zambia to evaluate intake of refined sugars: drinking sodas, chewing sugarcane, and adding large quantities of sugar to tea are all common habits.
  • HgbA1c may not be widely available; need to monitor serum glucose closely instead.
  • Rx in Zambia begins with metformin (sulfonylureas 2nd line); TZDs not generally available.
  • Management of diabetic pt on 2nd line ART (with PI) can be challenging due to lack of other ART options after 1st line NNRTI failure; monitor glucose more intensively in such pts. 

REFERENCES

Zambia Information Author: David Riedel, M.D.

CLINICAL

  • Insulin resistance (IR) common in HIV+ pts on ART.
  • Diabetes mellitus (DM) less common, but still 2-4x higher than in general population.
  • IR also caused by fat accumulation (lipodystrophy). In general population (and presumably in HIV+ pts), IR increases risk for coronary artery disease.
  • Risk factors for IR/DM: abdominal fat accumulation, peripheral lipoatrophy, family Hx of DM, obesity, age, HCV, low CD4 nadir, black/Hispanic race.
  • Consider role of other medications: corticosteroids, growth hormone, megestrol acetate, immunosuppressants, atypical antipsychotics.
  • PIs differ in effect on IR: IDV >> NFV, RTV, LPV/r > SQV, APV >> ATV.

DIAGNOSIS

  • DM = fasting glucose >126 mg/dL confirmed with a repeat test, or Sx of DM and a random plasma glucose >200 mg/dL.
  • HgbA1c underestimates glycemia in HIV+ pts on ART (~ HgbA1c 0.8% less than expected)
  • Impaired fasting glucose (IFG) = 100-125 mg/dL, at risk for developing DM per American Diabetes Association (ADA) definition.
  • If unclear, consider 2hr 75g oral glucose tolerance test (OGTT), more sensitive than fasting glucose: 140-199 = impaired glucose tolerance (IGT), >200 = DM.
  • IGT or IFG is considered pre-DM. HgbA1c 6.0-6.5% considered pre-DM in general population.
  • Check fasting glucose at baseline, prior to and 3 & 6 mos after ART initiation, then yearly if normal.
  • No accepted role for clinical use of insulin levels to assess IR.

TREATMENT

Diet, Exercise, Risk Factor Modification

  • Balanced diet and regular exercise crucial. ADA diet consisting of 50% carbohydrates (higher-fiber, unrefined preferred), 30% fat (unsaturated preferred), and 20% protein recommended.
  • Nutrition consultation recommended.
  • Modest weight loss (10%) in those with BMI >25 reduces glucose intolerance and can prevent onset of DM in non-HIV infected population at risk. Lifestyle modification shown to improve metabolic parameters in HIV-infected patients.
  • Aggressive risk factor modification for coronary disease: lipid control, HTN control (generally with ACE-I or ARB), smoking cessation, cocaine avoidance, aspirin therapy.
Medications (oral)

  • First line treatment for DM: metformin or thiazolidinediones (TZDs) such as rosiglitazone or pioglitazone.
  • Metformin: reduces hepatic IR. Associated with reduced visceral fat, BP, triglycerides (TG) (10-20%) in HIV+ pts. Some studies have shown decreased limb fat with metformin; use with caution in pts with lipoatrophy. Serum creat >1.5 mg/dL an absolute contraindication due to lactic acidosis risk. Also enhanced theoretical risk with NRTIs, liver disease, and CHF. GI upset most common. Start at 500 mg once-daily, titrate 500 mg weekly to 2 g twice-daily (max dose 850 3 times daily).
  • TZDs (pioglitazone and rosiglitazone): reduce peripheral IR as peroxisome proliferator-activated receptor (PPAR) gamma agonists. Effect on lipoatrophy controversial. Pioglitzaone may be better than rosiglitazone for lipoatrophy, but no head-to-head trials. Effect present only on those not on thymidine analogs. Some increase in TG with rosiglitazone but not pioglitazone. Rosiglitazone may increase CVD risk. Lipid profile with rosiglitazone less favorable than pioglitazone. Rosiglitazone: Start at 2 mg once-daily, titrate up to 8 mg once-daily. Pioglitazone: start at 15 mg, titrate up to 45 mg/d. Max effect seen after several wks. Fluid retention common. Avoid with CHF, liver disease. Reduced bone density and fractures associated with TZD use.
  • Combination of metformin and TZDs not established in HIV+ pts, but synergy expected.
  • Use sulfonylureas, meglitinides, exenatide, sitagliptin or acarbose as 2nd line therapies.
  • No accepted role for pharmacologic interventions for those with IR or pre-diabetes, though data are emerging.
Insulin

  • Consider low dose (10-15 units) bedtime glargine, detimer, or NPH insulin in combination with oral anti-diabetic agents if failing oral agents. Insulin effective for glucose control with individualized regimen.
  • Consider referral to diabetes expert.
Modification of ART

  • Consider switching from PI to NNRTI-based regimen provided viral control not jeopardized.
  • Although data limited, some PIs, especially ATV, may cause less insulin resistance.

Drug Comments

DrugRecommendations/Comments
insulin Many different choices. Regimen needs to be individualized. If glucose >250 mg/dL and/or HgbA1c >10%, pt will likely need insulin, at least initially. Once glucose controlled, some pts can be transitioned to oral agents alone. There is also growing consensus to add insulin earlier, i.e. after failure or 1 or 2 orals.
metformin Best drug for mild DM in setting of obesity. Nausea, diarrhea common initially; generally improves over time. Minimize by starting at a low dose and titrating upwards. Watch for lactic acidosis. Concerns about worsening lipoatrophy.
pioglitazone Good drug. Better lipid profile than rosiglitazone. Not associated with excess CVD risk. Used in largest TZD trial in HIV+ pts with lipoatrophy showing beneficial result. Bone issues important. 
rosiglitazone Mixed data in pts with lipoatrophy. Good DM drug. Triglycerides may increase. Associated with increased risk of CVD.
exenatide New DM drug. Works by increasing insulin secretion and decreasing glucagon. Also associated with modest weight loss. Given SC. No studies in HIV+ pts.

FOLLOW UP

Monitoring

  • Lifestyle changes only: self-monitored blood glucose weekly.
  • Oral agents: monitor fasting glucose q am.
  • Insulin: monitor glucose 2-4 x/d .
  • Pts with pre-DM should be screened at 3-6 mo intervals. After Dx of DM, monitor HgbA1c q 3-6 mos, depending on control. Goal <7%, with caveat regarding accuracy of A1c in HIV-infected persons. Fructosamine, which gives an integrated measure of glycemia over the previous 2 weeks, may be helpful.
  • Monitoring for complications: dilated fundoscopic exam by ophthalmology, spot urine for microalbumin and foot exam with inspection, monofilament, and vibration testing at baseline and q 6-12 mos.

REFERENCES

REFERENCED WITHIN THIS GUIDE


 
Diagnosis
 


Complications of Therapy


Malignancies


Miscellaneous


Opportunistic Infections


Organ System

Drugs
 


Antimicrobial Agents


Antiretrovirals


Miscellaneous

Guidelines
 


Zambia HIV National Guidelines

Management
 


Antiretroviral Therapy


Laboratory Testing


Miscellaneous

Pathogens
 


Bacteria


Fungi


Parasites


Viruses

View All Modules
 
Index
 
 
Contacts    Help    Copyright    Acknowledgments    Abbreviations